rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Elizabeth Forminard

EVP, Chief Legal Officer

Company insider

Files Form 4 as: EVP, Chief Legal Officer, Johnson & Johnson.

Every Form 4 they filed

In numbers

Trades disclosed
81
Buys
0
Sells
1
Bought
$0
Sold
$8.2M
Companies
1
Companies where not an officer
0
First trade
10 Feb 2023
Last trade
6 Aug 2026
Last filed
7 Aug 2026

Companies traded

Where they are an officer
JNJ Johnson & JohnsonOfficer · Pharmaceuticals · last 6 Aug 20260 buys · 1 sell

Activity over time

1 Aug – 1 Oct
101 Aug1 Sep1 Oct

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code M$1.2M9,344 at $131.94filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Sold$2.4M9,344 at $257.76filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Sold$1.7M6,574 at $255.93filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—9,344 at $0.00filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—9,344 at $0.00filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code M$1.2M9,344 at $131.94filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Sold$2.4M9,344 at $257.76filing
6 Aug 2026filed 7 Aug 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Sold$1.7M6,574 at $255.93filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—961 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—1,063 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code A—27,076 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code A—1,944 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—961 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code M—1,063 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code A—27,076 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & Johnsonoption or derivative · PharmaceuticalsSEC FORM 4 Code A—1,944 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code M—961 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code F$120K492 at $243.45filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code M—1,063 at $0.00filing
15 Feb 2026filed 18 Feb 2026JNJ Johnson & JohnsonPharmaceuticalsSEC FORM 4 Code F$132K544 at $243.45filing

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Daniel E. PintoDirector · Director at Johnson & Johnson, filing Form 4 there in the last year
Marillyn A. HewsonDirector · Director at Johnson & Johnson, filing Form 4 there in the last year
Eugene A. WoodsDirector · Director at Johnson & Johnson, filing Form 4 there in the last year
Timothy SchmidEVP, WW Chair, MedTech · EVP, WW Chair, MedTech at Johnson & Johnson, filing Form 4 there in the last year
Jennifer L. TaubertDirector · EVP, WWC. Innovative Medicine at Johnson & Johnson, filing Form 4 there in the last year
Lloyd DoggettRepresentative, TX-37 · Also traded JNJ in the last 90 days
Thomas H. Kean, Jr.Representative, NJ-07 · Also traded JNJ in the last 90 days
John BoozmanSenator, AR · Also traded JNJ in the last 90 days